Skip to main content

11-02-2021 | ASCO GU 2021 | Conference coverage | Video

Updated TheraP data further support LuPSMA for mCRPC

Michael Hofman presents additional data, including patient-reported outcomes, from the phase 2 TheraP study of lutetium-177-prostate-specific membrane antigen-617 in men with metastatic castration-resistant prostate cancer (3:16​).

Read transcript

2021 ASCO Annual Meeting coverage

Access news and expert commentary from the 2021 ASCO Annual Meeting

Image Credits